Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Name:	us-gaap_InventoryRawMaterialsNetOfReserves
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Significant Accounting Policies, Cash, Cash Equivalents and Short-term Investments, Inventory Valuation, and Research, Development and Patent Expenses (Details) (USD $)			3 Months Ended		9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Patents [Member]	Sep. 30, 2013 Patents [Member]	Sep. 30, 2014 Patents [Member]	Sep. 30, 2013 Patents [Member]	Sep. 30, 2014 Maximum [Member] Privately- and Publicly-Held Biotechnology Companies [Member]
Cash, cash equivalents and short-term investments
Ownership percentage in equity investments (in hundredths)							20.00%
Inventory valuation [Abstract]
Raw materials	$ 7,085,000	$ 8,033,000
Research, development and patent expenses [Abstract]
Write-down			$ 500,000	$ 200,000	$ 800,000	$ 400,000